On September 5, 2019 VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, reported that Jeff Baxter, President and CEO, will present at the H.C. Wainwright 21st Annual Global Investment Conference in New York City on Tuesday, September 10, 2019, at 8:20 AM ET (Press release, VBI Vaccines, SEP 5, 2019, View Source [SID1234539310]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

- Event: H.C. Wainwright 21st Annual Global Investment Conference
- Date: Tuesday, September 10, 2019
- Time: 8:20 – 8:45 AM ET
- Webcast: View Source

A live webcast of the presentation may also be accessed by visiting the Investors page of VBI’s website at www.vbivaccines.com.

On September 5, 2019 Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer, reported its participation in the following industry conferences in September (Press release, Unum Therapeutics, SEP 5, 2019, View Source [SID1234539309]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cell & Gene Therapy Bioprocessing & Commercialization, September 9 – 12, Boston, MA.

Geoffrey Hodge, Chief Technical Officer at Unum Therapeutics, will present "Designing the Cell Therapy Facility of the Future by Learning from the Past" on Tuesday, September 10, 2019 at 8:40 a.m. ET.
CAR-TCR Summit, September 10 – 13, Boston, MA.

David O’Donnell, Director, Technology Operations at Unum Therapeutics, will present "Managing Leukapheresis for Autologous Cell Therapies" on Tuesday, September 10, 2019 at 9:00 a.m. ET.

Ann Ranger, Ph.D., Senior Director, Translational Medicine and Biomarkers at Unum Therapeutics, will present "Clinical Pharmacology of a Unique Antibody Coupled T Cell (ACTR) Therapy Combination Product" on Thursday, September 12, 2019 at 1:00 p.m. ET.
2nd International Conference on Lymphocyte Engineering (ICLE), September 13 – 15, London, UK.

Seth Ettenberg, Ph.D., Chief Scientific Officer at Unum Therapeutics, will present "Addressing the Challenges of T Cell Therapies in Solid Tumors" on Friday, September 13, 2019 at 6:50 p.m. BST / 1:50 p.m. EDT in London, United Kingdom.

On September 5, 2019 Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, reported that the company is scheduled to present at the following upcoming investor conference (Press release, Trillium Therapeutics, SEP 5, 2019, View Source [SID1234539308]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright 21st Annual Global Investment Conference
Presenter: Dr. Bob Uger, Chief Scientific Officer and Interim President
Date and Time: September 10, 2019 at 4:40 p.m. ET
Location: Lotte New York Palace Hotel, New York City

A live audio webcast of the H.C. Wainwright 21st Annual Global Investment Conference presentation will be available under the investor relations section of Trillium’s website at www.trilliumtherapeutics.com.

On September 5, 2019 Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, reported that Ivan Bergstein, M.D., Stemline’s CEO, will present at the H.C. Wainwright 21st Annual Global Investment Conference on Monday, September 9, 2019 at 12:30 PM ET at the Lotte New York Palace Hotel (Press release, Stemline Therapeutics, SEP 5, 2019, View Source [SID1234539306]). A live webcast of the presentation can be viewed on the company’s website at www.stemline.com.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

About ELZONRIS
ELZONRIS (tagraxofusp-erzs), a CD123-directed cytotoxin, is approved by the U.S. Food and Drug Administration (FDA) and commercially available in the U.S. for the treatment of adult and pediatric patients, two years or older, with blastic plasmacytoid dendritic cell neoplasm (BPDCN). For full prescribing information in the U.S., visit www.ELZONRIS.com. In Europe, a marketing authorization application (MAA) is under review by the European Medicines Agency (EMA). ELZONRIS is also being evaluated in additional clinical trials in other indications including chronic myelomonocytic leukemia (CMML), myelofibrosis (MF), and acute myeloid leukemia (AML).

About BPDCN
BPDCN is an aggressive hematologic malignancy with historically poor outcomes and an area of unmet medical need. BPDCN typically presents in the bone marrow and/or skin and may also involve lymph nodes and viscera. The BPDCN cell of origin is the plasmacytoid dendritic cell (pDC) precursor. The diagnosis of BPDCN is based on the immunophenotypic diagnostic triad of CD123, CD4, and CD56, as well as other markers. For more information, please visit the BPDCN disease awareness website at www.bpdcninfo.com.

About CD123
CD123 is a cell surface target expressed on a wide range of myeloid tumors including blastic plasmacytoid dendritic cell neoplasm (BPDCN), certain myeloproliferative neoplasms (MPNs) including chronic myelomonocytic leukemia (CMML) and myelofibrosis (MF), acute myeloid leukemia (AML) (and potentially enriched in certain AML subsets), myelodysplastic syndrome (MDS), and chronic myeloid leukemia (CML). CD123 has also been reported on certain lymphoid malignancies including multiple myeloma (MM), acute lymphoid leukemia (ALL), hairy cell leukemia (HCL), Hodgkin’s lymphoma (HL), and certain Non-Hodgkin’s lymphomas (NHL). In addition, CD123 has been detected on some solid tumors as well as autoimmune disorders including cutaneous lupus and scleroderma.

On September 5, 2019 Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, reported that Brian M. Culley, Chief Executive Officer, will be presenting at the H.C. Wainwright 21st Annual Global Investment Conference on September 9th, 2019 at 11:15am Eastern Time at the Lotte New York Palace Hotel in the Louis Salon in New York, NY (Press release, Lineage Cell Therapeutics, SEP 5, 2019, View Source [SID1234539305]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Interested parties can access a live audio webcast on the Events and Presentations section of Lineage’s website and an archived presentation will be available for 30 days. Interested parties may follow @HCWCO on Twitter for the latest conference updates.